Merck and Simcere agree joint venture

Published: 22-Jul-2011
Finance Pharmaceutical

Will initially offer drugs for cardiovascular and metabolic diseases


Merck & Co, known as MSD outside the US and Canada, is to form a joint venture with China’s Simcere Pharmaceutical Group with the aim initially of offering branded pharmaceutical products for cardiovascular and metabolic diseases in China.

No financial details were given.

In the area of cardiovascular disease, the partnership will offer a combined portfolio of drugs, which includes Merck’s Zocor (simvastatin), Cozaar (losartan) and Renitec (enalapril) and Simcere’s Xinta (levamlodipine) and Shufutan (rosuvastatin).

In the metabolic disease area, the partnership aims to maximise access in China to sitagliptin, a DPP-IV inhibitor for the treatment of type 2 diabetes.

  • Companies:
  • Merck MSD
  • Simcere Pharmaceutical Group
See more

You may also like

Manufacturing

Merck expands newest biologics testing centre in Shanghai

Read more
New labs complete the second phase of the company’s €29m biologics testing centre, which was opened in 2022

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Adult vaccination programmes deliver significant socio-economic benefits, study finds The study shows that adult immunisation programmes return 19x their initial investment, which could ease the pressure on health systems
  3. The colouration of tablets and capsules Paul Smith from Sensient Pharmaceutical Technologies discusses the use of colour in solid oral dosage forms
  4. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
  5. Production of pharmaceutical compounds through microbial fermentation Most people’s experience of fermentation will be through its most famous and popular use – the brewing of beer

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Manufacturing

Merck expands newest biologics testing centre in Shanghai

New labs complete the second phase of the company’s €29m biologics testing centre, which was opened in 2022
Research & Development

Astex enters into agreement with Merck to identify small molecule candidates

Astex Pharmaceuticals has entered into an exclusive research collaboration with Merck to identify small molecule candidates with activity towards a tumour suppressor protein for the treatment of cancer
Research & Development

Merck and SignalChem to investigate combination tumour treatment

The companies will evaluate SignalChem’s SLC-391 in combination with Merck’s Keytruda (pembrolizumab) in the treatment of Advanced Non-Small Cell Lung Cancer
Drug Delivery

Merck launches VirusExpress platform for cell and gene therapies

The platform helps to overcome lentiviral production challenges and can reduce process development time by approximately 40%, Merck says
Manufacturing

Achieve greater upstream productivity with intensified processing

New App Note from Merck on the use of perfusion technologies
Pharmaceutical

Evotec agrees to give US Merck access to facility of the future

MSD has paid $15m to gain access to Just–Evotec Biologics’ J.POD Washington facility that conducts small, intensified bioprocessing operations housed inside autonomous cleanrooms
Pharmaceutical

US Merck backs college course to create workforce for $1bn expansion

The curriculum will focus on biotechnology, process engineering and workforce development to create a ready made workforce to fill 100 new jobs at expanding Virginia facility
Subscribe now